| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 2 | 13 | -0,34 % | ||
| CUREVAC | 2 | 9 | -0,30 % | ||
| ABCELLERA BIOLOGICS | 2 | 1 | -2,15 % | ||
| BIOGEN | 1 | 54 | +0,35 % | ||
| MODERNA | 1 | 16 | +1,92 % | ||
| ALNYLAM PHARMACEUTICALS | 1 | 9 | +0,49 % | ||
| EXELIXIS | 1 | 8 | -0,16 % | ||
| INSMED | 1 | 7 | 0,00 % | ||
| TEMPUS AI | 1 | 1 | 0,00 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | -2,20 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:30 | Curevac-Aktie steht urplötzlich im Kreuzfeuer der Spekulanten - im Orderbuch zeigen sich merkwürdige Bewegungen - jetzt trennt sich die Spreu vom Weizen - Zuschauer werden bestraft. | Hebelschein-Spekulant | |||
| 10:26 | ANAVEX LIFE SCIENCES CORP - Absturz unausweichlich! | 2 | Maximilian Berger | ||
| 07:15 | Medizinisches Cannabis im Wandel: Neue Chancen für stationäre Anbieter wie Hanf.com, MindMed und Tilray | Small- & Micro Cap Investment | |||
| Fr | If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today | 2 | Benzinga.com | ||
| Fr | Why Tempus AI Stock Soared This Week | 9 | The Motley Fool | ||
| Fr | AbCellera Biologics wechselt Wirtschaftsprüfer: Ernst & Young folgt auf KPMG ab 2026 | 4 | Investing.com Deutsch | ||
| Fr | Hedge Fund and Insider Trading News: Ray Dalio, Michael Burry, Marshall Wace, Exelixis Inc (EXEL), Monolithic Power Systems Inc (MPWR), and More | 4 | Insider Monkey | ||
| Fr | AbCellera Biologics Inc. - 8-K, Current Report | 9 | SEC Filings | ||
| Fr | Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot | 6 | Benzinga.com | ||
| Fr | What's Going On With Alnylam Stock On Friday? | 8 | Benzinga.com | ||
| Fr | If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today | 2 | Benzinga.com | ||
| Fr | Absci stock price target raised to $9 from $8 at Jones Trading | 1 | Investing.com | ||
| Fr | FDA re-review of Vanda tradipitant partial clinical hold extended | 3 | Seeking Alpha | ||
| Fr | BioNTech: CureVac-Übernahme kurz vor Abschluss | 550 | börsennews.de | Die BioNTech-Aktie wird aktuell bei 88 EUR gehandelt und gewinnt wieder an Dynamik. Während die Übernahme von CureVac in ihre finale Phase eintritt, sorgen gleichzeitig neue Forschungs-Updates und Analystenkommentare... ► Artikel lesen | |
| Fr | Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations | 1 | Insider Monkey | ||
| Fr | FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up | 10 | Benzinga.com | ||
| Fr | Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 | 1 | Benzinga.com | ||
| Fr | ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? | 1 | Zacks | ||
| Fr | Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? | 27 | Zacks | ||
| Fr | Neurocrine Bio. stock jumps as rival drug faces modest Medicare price cut | 3 | Investing.com |